In a strategic move to enhance healthcare accessibility, U.S. President Donald Trump announced a groundbreaking deal with pharmaceutical giants Eli Lilly and Novo Nordisk. The initiative seeks to dramatically lower the cost of GLP-1 weight-loss drugs, providing significant savings for Medicare and Medicaid participants as well as cash payers.
